# Progress Note 03 — Annual Wellness Visit, Subsequent

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

- Patient: Johnny Cash (real historical name used in a fictional teaching record)
- Synthetic MRN: HR-ML004-SYN
- Date: 2026-04-24
- Fictional facility: St. Posthumous Health Center
- Fictional author: Gideon Hale, MD
- Calendar frame: modern shifted

- Visit type: Annual Wellness Visit, Subsequent
- Services: HCPCS G0439 (subsequent annual wellness visit) with CPT 99497 (advance care planning), both on the same day

## Chief complaint

Subsequent annual wellness visit; no new complaints. **S**

## History of present illness

Mr. Cash is a 71-year-old man with type 2 diabetes complicated by autonomic and peripheral neuropathy, neurogenic orthostatic hypotension, and severe primary open-angle glaucoma, who returns for his subsequent annual wellness visit four weeks after his endocrinology consultation. Sitagliptin and low-dose midodrine were started then. He completed the health risk assessment before the visit, with a family member reading the questions aloud because of his low vision. He stands up in stages, sleeps with the head of the bed raised, and wears waist-high compression; the lightheadedness on standing is less frequent, and he has had no falls since the consultation. His home glucose readings show no values below 70 mg/dL. He uses both eye drops as prescribed and has added no over-the-counter medicines. He is recording at home and writing most days. **S**

| Element | Detail |
|---|---|
| Visit | Subsequent annual wellness visit |
| Context | Health risk assessment completed before the visit with a family member reading the questions |
| Safety events | No falls since the endocrinology consultation; no emergency visits or hospital stays since his first visit |
| Medicines | Adherent; pill organizer filled by a family member; both eye drops in use; no new over-the-counter medicines |
| Active conditions | Type 2 diabetes with autonomic and peripheral neuropathy, orthostatic hypotension, glaucoma, mild diabetic retinopathy, and hyperlipidemia |
| Functional status | Independent in basic activities of daily living; walks with a cane; does not drive |

## Health risk assessment

Completed by the patient before the visit and reviewed during the visit. **S**

| Domain | Finding |
|---|---|
| Self-rated health | Fair, and better since standing up has become easier |
| Psychosocial | A family member helps at home and comes to visits; active church community; writing and recording at home give purpose; no loneliness reported |
| Behavioral | No tobacco use; no alcohol; walks short distances with a cane; follows a carbohydrate-consistent diet; sleeps about seven hours |
| Activities of daily living | Independent in bathing, dressing, eating, toileting, and transfers |
| Instrumental activities of daily living | Manages his own money and telephone; a family member fills his pill organizer and drives him |
| Home safety | Smoke detectors working; dim hallway and stair lighting; handrail on one side of the stairs only |
| Falls | Two falls in the six months before his first visit, none since the consultation; afraid of falling again |
| Hearing and vision | No hearing concern; tunnel vision and difficulty in dim light from glaucoma; dilated eye examination two months ago |
| Bladder | No urgency, incontinence, or difficulty emptying |
| Memory | No concerns from him or his family |

## Review of systems

| System | Result | Finding |
|---|---|---|
| Constitutional | Negative | Weight down about 1 kg since the consultation with diet; no fever or appetite change |
| Eyes | Positive | Long-standing tunnel vision and poor vision in dim light; no eye pain, redness, or stinging from the drops |
| Ears, nose, mouth, and throat | Negative | No hearing change or mouth sores |
| Cardiovascular | Positive | Lightheaded on standing quickly, less often than before; no fainting, chest pain, palpitations, or ankle swelling |
| Respiratory | Negative | No cough, sputum, or breathlessness |
| Gastrointestinal | Negative | No nausea, diarrhea, or constipation on metformin |
| Genitourinary | Negative | No urinary urgency, incontinence, or retention |
| Musculoskeletal | Positive | Leg weakness; walks with a cane; no falls since the consultation |
| Integumentary | Negative | No foot sores, blisters, or color change on daily foot checks |
| Neurological | Positive | Numbness of both feet to the ankles, unchanged; no new weakness or headache |
| Psychiatric | Negative | Mood good; sleeps well; PHQ-2 score 0 |
| Endocrine | Negative | No shakiness, sweating, or confusion suggesting low glucose; no excess thirst or urination |
| Hematologic | Negative | No easy bruising or bleeding |

13 systems reviewed. **S**

## Current medications

- Metformin 1000 mg oral tablet, one tablet by mouth twice daily with meals **S**
- Sitagliptin 100 mg oral tablet, one tablet by mouth daily **S**
- Atorvastatin 40 mg oral tablet, one tablet by mouth daily **S**
- Latanoprost 0.005% ophthalmic solution, one drop in each eye at bedtime **S**
- Dorzolamide 2% ophthalmic solution, one drop in each eye twice daily **S**
- Midodrine 2.5 mg oral tablet, one tablet by mouth three times daily, last dose by 6 PM **S**

## Allergies

- No known allergy **S**

## Objective

BP 138/76 mmHg; pulse 75 bpm; respirations 16/min; temperature 36.6 °C; oxygen saturation 95% on room air; weight 94.2 kg; BMI 26.7 kg/m². All vital signs are synthetic.

PHQ-2: 0; AUDIT-C: 0. All results are synthetic.

## Change since baseline

- PHQ-2: 1 at baseline, 0 at this visit **S**

## Physical examination

| System | Finding |
|---|---|
| Constitutional | Alert, wry, and well-appearing; weight 94.2 kg, down from 95.0 kg at the consultation |
| Eyes | Conjunctivae quiet; pupils equal; constricted fields to confrontation in both eyes |
| Ears, nose, and throat | Canals clear; oral mucosa moist |
| Neck | No thyroid enlargement or nodes; no carotid bruits |
| Cardiovascular | Regular rhythm; no murmur; blood pressure 138/76 mmHg seated and 116/70 mmHg after three minutes standing, heart rate 75 to 78, with mild lightheadedness; no edema |
| Respiratory | Clear to auscultation bilaterally |
| Abdomen | Soft and non-tender; no masses or aortic bruit |
| Feet | Skin intact with no ulcers or calluses; 10-g monofilament and vibration sensation reduced to the ankles in both feet; dorsalis pedis and posterior tibial pulses present; well-fitting protective shoes |
| Musculoskeletal | Timed Up and Go 14 seconds with a cane; needs his arms to rise from a chair |
| Neurological | Oriented; conversation, recall, and reasoning normal by direct observation; reduced ankle reflexes |
| Psychiatric | Euthymic and engaged; judgment and insight intact |
| Skin | No suspicious lesions on the exposed skin |

All examination findings are synthetic. **S**

## Assessment and plan

1. **Subsequent annual wellness visit completed**. Health risk assessment reviewed, personalized prevention plan updated, and a large-print copy given. Depression and alcohol screens are negative. Cognition is normal by direct observation, and the Mini-Cog at the first visit two months ago was 5 of 5, so it was not repeated. Fall risk is high. **S**
   - Next annual wellness visit in one year.
2. **Type 2 diabetes with diabetic autonomic neuropathy** (E11.43). HbA1c 8.6% at the first visit, above his individualized goal below 7.5%. Home readings have improved since sitagliptin was added, with no hypoglycemia. Kidney screening is current: urine albumin-creatinine ratio 18 mg/g and eGFR 72 mL/min/1.73 m², both normal. **S**
   - Continue metformin 1000 mg twice daily and sitagliptin 100 mg daily.
   - HbA1c and lipids at the three-month review in about five weeks; urine albumin-creatinine ratio and eGFR yearly.
3. **Neurogenic orthostatic hypotension** (I95.1). Standing systolic pressure 116 mmHg, up from 112 mmHg at the first visit, on midodrine 2.5 mg three times daily. Still mildly symptomatic. **S**
   - Continue midodrine with the last dose at least four hours before bed, staged standing, head-of-bed elevation, compression, and 2 liters of fluid a day.
   - Review the dose at the three-month visit, with a supine blood pressure check.
4. **Diabetic peripheral neuropathy with loss of protective sensation** (E11.42). Foot examination today shows no ulcer or pre-ulcerative lesion; sensory loss unchanged. **S**
   - Daily self-inspection with a family member's help because of his vision.
   - Continue protective footwear; foot examination at every visit.
5. **Primary open-angle glaucoma, severe stage** (H40.1133). Eye pressures were above target at the first visit, and dorzolamide was added to latanoprost. The dilated eye examination two months ago also covered diabetic retinopathy screening. Neither drop lowers blood pressure or heart rate. **S**
   - Continue latanoprost and dorzolamide.
   - Eye pressure check at the three-month review; OCT and visual fields at six months with the eye clinic.
6. **High fall risk**. Orthostatic hypotension, loss of foot sensation, leg weakness, low vision, and earlier falls. Timed Up and Go 14 seconds with a cane. **S**
   - Refer to physical therapy for gait, strength, and balance training.
   - Refer to low-vision rehabilitation for a home lighting and safety review, including a second stair handrail.

## Personalized prevention plan

A written copy was given to the patient. **S**

| Service | Status | Detail |
|---|---|---|
| Influenza vaccine | Up to date | High-dose vaccine given last season; next dose due when the next season's vaccine is available |
| COVID-19 vaccine | Due | Recommended at his age and with diabetes; he will get it at his pharmacy |
| Pneumococcal vaccine | Up to date | PCV20 given at the first visit two months ago; no further doses needed |
| Recombinant zoster vaccine | Due | Dose 1 planned for the three-month review, dose 2 two to six months later |
| RSV vaccine | Due | Recommended at 60 to 74 with diabetes and its complications; single dose before the respiratory season |
| Tetanus booster | Due | No booster on record; he will check his pharmacy records |
| Diabetic eye examination | Up to date | Dilated examination two months ago with the eye clinic, which follows his glaucoma and mild retinopathy; repeat yearly |
| Diabetic foot examination | Completed today | No ulcer; loss of protective sensation known; examined at every visit |
| Kidney screening | Up to date | Urine albumin-creatinine ratio and eGFR normal at the first visit; repeat yearly |
| Cholesterol | Up to date | LDL 128 mg/dL before atorvastatin; repeat at the three-month review |
| Depression screening | Completed today | PHQ-2 score 0 |
| Alcohol misuse screening | Completed today | AUDIT-C score 0 |
| Cognitive assessment | Completed today | Normal by direct observation; Mini-Cog 5 of 5 two months ago |
| Falls prevention | Referred | Physical therapy for gait and balance and low-vision rehabilitation for home safety |
| Colorectal cancer screening | Ordered | No screening result on file; stool FIT kit given, to be returned by mail |
| Hepatitis C screening | Ordered | One-time screening recommended for all adults through age 79; added to the three-month laboratory tests |
| Prostate cancer screening | Not indicated | Not recommended at 70 or older |
| Lung cancer and abdominal aortic aneurysm screening | Not indicated | No tobacco use is recorded in his social history |

## Advance care planning

Voluntary advance care planning discussion of about 20 minutes, with his consent. He has a written health care directive and has named a health care agent; a copy is now in the chart. He described what matters most to him: keeping the sight he has left, staying at home, and continuing to write and record. The discussion covered how to make his wishes known if he could not speak for himself and how to keep the directive with his agent. He will review his wishes with his agent and revisit them at a future visit. **S**

## Guideline basis

- Standards of Care in Diabetes—2025 (2025), American Diabetes Association
- CMID: Clinical Monitoring Intelligence Database, diabetes, glaucoma, and hyperlipidemia monographs (2026), Aether Forge
- Medicare Wellness Visits (Medicare Learning Network) (2026), Centers for Medicare & Medicaid Services
- Medicare Preventive Services reference: visit templates, screening cascades, and documentation elements (2026), Aether Forge

## Follow-up

- Physical therapy and low-vision rehabilitation referrals placed. Return the FIT kit by mail. Three-month diabetes, blood pressure, and eye pressure review in about five weeks, with HbA1c, lipids, hepatitis C screening, and the first zoster dose. Next annual wellness visit in one year. **S**
- Next scheduled visit 2026-05-29: three-month diabetes, blood pressure, and eye pressure review. **S**
